Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates
- PMID: 30684003
- PMCID: PMC6447515
- DOI: 10.1007/s00262-019-02302-2
Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates
Abstract
In cancer, infection and inflammation, the immune system's function can be dysregulated. Instead of fighting disease, immune cells may increase pathology and suppress host-protective immune responses. Myeloid cells show high plasticity and adapt to changing conditions and pathological challenges. Despite their relevance in disease pathophysiology, the identity, heterogeneity and biology of myeloid cells is still poorly understood. We will focus on phenotypical and functional markers of one of the key myeloid regulatory subtypes, the myeloid derived suppressor cells (MDSC), in humans, mice and non-human primates. Technical issues regarding the isolation of the cells from tissues and blood, timing and sample handling of MDSC will be detailed. Localization of MDSC in a tissue context is of crucial importance and immunohistochemistry approaches for this purpose are discussed. A minimal antibody panel for MDSC research is provided as part of the Mye-EUNITER COST action. Strategies for the identification of additional markers applying state of the art technologies such as mass cytometry will be highlighted. Such marker sets can be used to study MDSC phenotypes across tissues, diseases as well as species and will be crucial to accelerate MDSC research in health and disease.
Keywords: Human; Mouse; Mye-EUNITER; Myeloid-derived suppressor cells; Non-human primates.
Conflict of interest statement
The authors declare no competing interests.
Figures

Similar articles
-
Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation.J Immunother Cancer. 2020 Sep;8(2):e001223. doi: 10.1136/jitc-2020-001223. J Immunother Cancer. 2020. PMID: 32907925 Free PMC article.
-
How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions.Cancer Immunol Immunother. 2019 Apr;68(4):631-644. doi: 10.1007/s00262-018-2170-8. Epub 2018 May 21. Cancer Immunol Immunother. 2019. PMID: 29785656 Free PMC article. Review.
-
Immunophenotyping of Circulating Myeloid-Derived Suppressor Cells (MDSC) in the Peripheral Blood of Cancer Patients.Methods Mol Biol. 2021;2236:1-7. doi: 10.1007/978-1-0716-1060-2_1. Methods Mol Biol. 2021. PMID: 33237535
-
Plasticity of myeloid-derived suppressor cells in cancer.Curr Opin Immunol. 2018 Apr;51:76-82. doi: 10.1016/j.coi.2018.03.009. Epub 2018 Mar 14. Curr Opin Immunol. 2018. PMID: 29547768 Free PMC article. Review.
-
Myeloid-derived suppressor cells in lymphoma: The good, the bad and the ugly.Blood Rev. 2018 Nov;32(6):490-498. doi: 10.1016/j.blre.2018.04.006. Epub 2018 Apr 19. Blood Rev. 2018. PMID: 29691090 Review.
Cited by
-
Dual roles of myeloid-derived suppressor cells in various diseases: a review.Arch Pharm Res. 2024 Jul;47(7):597-616. doi: 10.1007/s12272-024-01504-2. Epub 2024 Jul 15. Arch Pharm Res. 2024. PMID: 39008186 Review.
-
High-Throughput Screening and Proteomic Characterization of Compounds Targeting Myeloid-Derived Suppressor Cells.Mol Cell Proteomics. 2023 Sep;22(9):100632. doi: 10.1016/j.mcpro.2023.100632. Epub 2023 Aug 14. Mol Cell Proteomics. 2023. PMID: 37586548 Free PMC article.
-
Mechanisms Underlying the Role of Myeloid-Derived Suppressor Cells in Clinical Diseases: Good or Bad.Immune Netw. 2021 May 26;21(3):e21. doi: 10.4110/in.2021.21.e21. eCollection 2021 Jun. Immune Netw. 2021. PMID: 34277111 Free PMC article. Review.
-
Role of Myeloid-derived suppressor cell (MDSC) in autoimmunity and its potential as a therapeutic target.Inflammopharmacology. 2021 Oct;29(5):1307-1315. doi: 10.1007/s10787-021-00846-3. Epub 2021 Jul 20. Inflammopharmacology. 2021. PMID: 34283371 Review.
-
New Perspectives on Myeloid-Derived Suppressor Cells and Their Emerging Role in Haematology.J Clin Med. 2022 Sep 10;11(18):5326. doi: 10.3390/jcm11185326. J Clin Med. 2022. PMID: 36142973 Free PMC article. Review.
References
-
- Mitroulis I, Ruppova K, Wang B, Chen LS, Grzybek M, Grinenko T, Eugster A, Troullinaki M, Palladini A, Kourtzelis I, Chatzigeorgiou A, Schlitzer A, Beyer M, Joosten LAB, Isermann B, Lesche M, Petzold A, Simons K, Henry I, Dahl A, Schultze JL, Wielockx B, Zamboni N, Mirtschink P, Coskun Ü, Hajishengallis G, Netea MG, Chavakis T. Modulation of myelopoiesis progenitors is an integral component of trained immunity. Cell. 2018;172:147–161.e12. doi: 10.1016/j.cell.2017.11.034. - DOI - PMC - PubMed
-
- Hérault A, Binnewies M, Leong S, Calero-Nieto FJ, Zhang SY, Kang YA, Wang X, Pietras EM, Chu SH, Barry-Holson K, Armstrong S, Göttgens B, Passegué E. Myeloid progenitor cluster formation drives emergency and leukaemic myelopoiesis. Nature. 2017;544:53–58. doi: 10.1038/nature21693. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources